Objectives: To evaluate the feasibility of HPV testing, to specify its indications, results and associated cervical lesions at the Institut d’Hygiène Sociale hospital in Dakar between January 1, 2022 and December 31, 2024. Patients and Methods: This was a retrospective, descriptive and analytical study conducted over a 36-month period from January 1, 2022, to December 31, 2024, covering all patients who underwent colposcopy and/or biopsy according to indications and HPV testing at the Institut d’Hygiène Sociale Hospital in Dakar. Analysis was performed using Excel, Epi Info and RStudio software. Results: We collected 150 colonoscopic examinations. The average age of patients was 51.37, ranging from 30 to 83 years. Mean gestational age was 4.73 with extremes of 0 and 10, mean parity 3.96 and extremes 0 and 9. Age at first intercourse was available for 44 patients. The mean age was 21.71, with extremes of 13 and 38. The age at first intercourse was ≤20 years for 15 patients (34.09%), between 21 and 30 years for 26 patients (59.09%), and between 31 and 40 years for 3 patients (6.82%). There were 57 married women (84.29%), with 14.29% remarried. In relation to the period of genital activity, 61.43% of patients were menopausal. We performed 51 biopsies according to colposcopy indications and recorded 18 CIN1 (38.30%), 12 CIN2 (25.53%), 6 CIN3 (12.77%), 2 carcinomas (4.26%) and 9 cervicitis (19.15%). The rate of HPV testing among the 71 patients was 47.33% for colposcopies. HPV test results were not available for 5 patients (7.04%). In the remaining 66 patients, the test was negative in 52.11% and positive in 40.85% with an HPV HR. Some patients presented high-grade lesions with a negative HPV test, even after a second sampling for control. Other patients were HPV HR positive with CIN-like lesions. The HPV HR genotypes found were: 16, 18 and 45, found 3 times, 6 times and 3 times respectively. HPV 26, 33 and 52 were found 5 times, and 58 was found 8 times. Among our patients, 7 or 24.13% were carriers of one type, 10 or 34.48% were carriers of two HPV types, 8 were carriers of three or more HPV types, 4 were unspecified and 5 tests were unavailable. The bivariate analysis was not significant, probably due to sample size. Conclusion: Despite the very high sensitivity of the HPV test, which makes it highly recommended for cervical lesion screening, our study showed that HPV testing and genotyping are not 100% sensitive. A cytological examination is therefore strongly recommended for all
References
[1]
de Martel, C., et al. (2019) Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis. The Lancet Global Health, 8, e180-e190. https://pubmed.ncbi.nlm.nih.gov/31862245/
[2]
Bruni, L., Diaz, M., Castellsagué, X., Ferrer, E., Bosch, F.X. and de Sanjosé, S. (2010) Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. The Journal of Infectious Diseases, 202, 1789-1799. https://doi.org/10.1086/657321
[3]
Ferlay, J., Laversanne, M., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., et al. (2024) Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer. https://gco.iarc.fr/tomorrow
[4]
Baldauf, J., Averous, G., Baulon, E., Thoma, V., Talha-Vautravers, A., Sananes, N., et al. (2013) Néoplasies intraépithéliales du col. EMC-Gynécologie, 8, 1-21. https://doi.org/10.1016/s0246-1064(12)54837-1
[5]
Ongtengco, N., Thiam, H., Collins, Z., De Jesus, E.L., Peterson, C.E., Wang, T., et al. (2020) Role of Gender in Perspectives of Discrimination, Stigma, and Attitudes Relative to Cervical Cancer in Rural Sénégal. PLOS ONE, 15, e0232291. https://doi.org/10.1371/journal.pone.0232291
[6]
Mbaye, E.H.S., Gheit, T., Dem, A., McKay-Chopin, S., Toure-Kane, N.C., Mboup, S., et al. (2013) Human Papillomavirus Infection in Women in Four Regions of Senegal. Journal of Medical Virology, 86, 248-256. https://doi.org/10.1002/jmv.23719
[7]
Traore, S. (2004) Screening for CIN by Visual Inspection with Acetic Acid and Lugol’s Iodine: 4632 Women Screened in the District of Bamako. Thesis, Med. Faculté de Médecine de Bamako, 140 p.
[8]
Smith, J.S., Melendy, A., Rana, R.K. and Pimenta, J.M. (2008) Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review. Journal of Adolescent Health, 43, S5.e1-S5.e62. https://doi.org/10.1016/j.jadohealth.2008.07.009
[9]
Boly, M. (2023) Prevalence of Human Papillomavirus in the Incidence of Pre-Cancerous Cervical Lesions in the General Population of Koulikoro. Library of the Faculty of Medicine, Pharmacy and Dentistry.
[10]
Ndiaye, B., Sy, M., Diao, F.D., Diop, A., Thiam, M.S., Sene, A., et al. (2024) High-Risk HPV Detection and Cytological Correlation in Cervical Cancer Screening: A Cross-Sectional Study in Dakar, Senegal. Open Journal of Medical Microbiology, 14, 215-224. https://doi.org/10.4236/ojmm.2024.144016
[11]
Youssef, M.A., Abdelsalam, L., Harfoush, R.A., Talaat, I.M., Elkattan, E., Mohey, A., et al. (2016) Prevalence of Human Papilloma Virus (HPV) and Its Genotypes in Cervical Specimens of Egyptian Women by Linear Array HPV Genotyping Test. Infectious Agents and Cancer, 11, Article No. 6. https://doi.org/10.1186/s13027-016-0053-1
[12]
Tebeu, P.M., Ako, A., Nguefack, T.C., Tseunwo, T.C., Kengne, F.G. and Sando, Z. (2008) Epidemiology of the Infection in HPV in Semi-Urban Region of Cameroon: The Experience of the District of Health of Baham, West-Cameroon. Health Sciences and Disease, 19, 40-45.
[13]
de Sanjose, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., et al. (2010) Human Papillomavirus Genotype Attribution in Invasive Cervical Cancer: A Retrospective Cross-Sectional Worldwide Study. The Lancet Oncology, 11, 1048-1056. https://doi.org/10.1016/s1470-2045(10)70230-8
[14]
Kitchener, H., Almonte, M., Gilham, C., Dowie, R., Stoykova, B., Sargent, A., et al. (2009) ARTISTIC: A Randomised Trial of Human Papillomavirus (HPV) Testing in Primary Cervical Screening. Health Technology Assessment, 13, 1-150, iii-iv. https://doi.org/10.3310/hta13510
[15]
Gustafson, E.A., Santa Rosario, J.C., Rios-Bedoya, C. and de Socarraz, M. (2023) High Risk HPV Testing for Cervical Cancer Screening in a Puerto Rican Population. Gynecologic Oncology Reports, 48, Article ID: 101236. https://doi.org/10.1016/j.gore.2023.101236
[16]
Smith, E.M., Ritchie, J.M., Levy, B.T., et al. (2003) Prevalence and Persistence of Human Papillomavirus in Postmenopausl Age Women. Cancer Detection and Prevention, 27, 472-480.
[17]
Food and Drug Administration (2014) FDA News Release, FDA Approve First Human Pappillomasvirus Test for Primary Cervical Cancer Screening.
[18]
Goodman, A. (2015) HPV Testing as a Screen for Cervical Cancer. BMJ, 350, h2372. https://doi.org/10.1136/bmj.h2372
[19]
Bosch, F.X., Manos, M.M., Munoz, N., Sherman, M., Jansen, A.M., Peto, J., et al. (1995) Prevalence of Human Papillomavirus in Cervical Cancer: A Worldwide Perspective. JNCI Journal of the National Cancer Institute, 87, 796-802. https://doi.org/10.1093/jnci/87.11.796
[20]
Walboomers, J.M., de Roda Husman, A.M., Snijders, P.J., Stel, H.V., Risse, E.K., Helmerhorst, T.J., et al. (1995) Human Papillomavirus in False Negative Archival Cervical Smears: Implications for Screening for Cervical Cancer. Journal of Clinical Pathology, 48, 728-732. https://doi.org/10.1136/jcp.48.8.728
[21]
Cuzick, J., Terry, G., Ho, L., Monaghan, J., Lopes, A., Clarkson, P., et al. (2000) Association between High-Risk HPV Types, HLA DRB1 and DQB1 Alleles and Cervical Cancer in British Women. British Journal of Cancer, 82, 1348-1352. https://doi.org/10.1054/bjoc.1999.1103
[22]
de Roda Husman, A., Snijders, P., Stel, H., van den Brule, A., Meijer, C. and Walboomers, J. (1995) Processing of Long-Stored Archival Cervical Smears for Human Papillomavirus Detection by the Polymerase Chain Reaction. British Journal of Cancer, 72, 412-417. https://doi.org/10.1038/bjc.1995.347
[23]
Herrington, C.S. (1995) Review Human Papillomaviruses (HPV) in Gynaecological Cytology: From Molecular Biology to Clinical Testing. Cytopathology, 6, 176-189. https://doi.org/10.1111/j.1365-2303.1995.tb00471.x
[24]
Burger, M., Hollema, H., Pieters, W., Schröder, F. and Quint, W. (1996) Epidemiological Evidence of Cervical Intraepithelial Neoplasia without the Presence of Human Papillomavirus. British Journal of Cancer, 73, 831-836. https://doi.org/10.1038/bjc.1996.146
[25]
Clavel, C., Masure, M., Bory, J., Putaud, I., Mangeonjean, C., Lorenzato, M., et al. (1999) Hybrid Capture II-Based Human Papillomavirus Detection, a Sensitive Test to Detect in Routine High-Grade Cervical Lesions: A Preliminary Study on 1518 Women. British Journal of Cancer, 80, 1306-1311. https://doi.org/10.1038/sj.bjc.6690523
[26]
Cuzick, J., Sasieni, P., Davies, P., Adams, J., Normand, C., Frater, A., et al. (2000) A Systematic Review of the Role of Human Papilloma Virus (HPV) Testing within a Cervical Screening Programme: Summary and Conclusions. British Journal of Cancer, 83, 561-565. https://doi.org/10.1054/bjoc.2000.1375
[27]
Khunamornpong, S., Settakorn, J., Sukpan, K., Suprasert, P., Srisomboon, J., Intaraphet, S., et al. (2016) Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-Risk HPV Test in Northern Thailand. PLOS ONE, 11, e0158184. https://doi.org/10.1371/journal.pone.0158184
[28]
Hamers, F.F., Woronoff, A.S. and French Network of Cancer Registries (FRANCIM) (2019) Cervical Cancer in France: Trends in Incidence and Mortality up to 2018. Bulletin Epidémiologique Hebdomadaire, No. 22-23, 410-416. http://beh.santepubliquefrance.fr/beh/2019/22-23/2019_22-23_1.html
[29]
Ronco, G., Dillner, J., Elfström, K.M., Tunesi, S., Snijders, P.J.F., Arbyn, M., et al. (2014) Efficacy of HPV-Based Screening for Prevention of Invasive Cervical Cancer: Follow-Up of Four European Randomised Controlled Trials. The Lancet, 383, 524-532. https://doi.org/10.1016/s0140-6736(13)62218-7
[30]
Cochrane Database of Systematic Reviews (2018) Assessment of Diagnostic Test Accuracy Studies (QUADAS) Tool. John Wiley & Sons, Ltd.
